Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
MAPS reports results from a randomized, blinded Phase 3 trial of MDMA-assisted therapy for severe, chronic PTSD (90 people, average 14 years of PTSD). After three MDMA-assisted therapy sessions, 67% of treated participants no longer met the study's PTSD diagnosis and 88% had a clinically meaningful symptom drop, compared with…
Project Twenty21 collected real-world data from people in the UK who sought prescribed medicinal cannabis. Data at treatment start were available for 2,833 patients and 1,410 had 3-month follow-up for anxiety, chronic pain or PTSD. On average, patients reported improvements in condition-specific symptoms and in general health and quality of…
This prospective observational study followed 438 adults who were new medical‑marijuana patients in Pennsylvania. Using the SF‑36 survey, participants reported statistically significant improvements in all eight areas of health‑related quality of life from before starting medical marijuana to three months later (P < .001 for all domains). Older participants showed…
This large Australian real-world study followed 2,353 adults who were newly prescribed medicinal cannabis oil and found that patient-reported quality of life, fatigue, sleep, pain (in people with chronic pain), and mood (in people with anxiety or depression) showed statistically significant and clinically meaningful improvements that were maintained up to…
